Nose-to-brain delivery allows application of drugs at the roof of the nasal cavity, which are transported to the central nervous system (CNS) of humans (A) and rodents (B). Nose-to-brain transport can either be mediated via the olfactory or the trigeminal pathway. Drugs passing along the olfactory...
SYNCROSOME provides frozen or fixed slices of different tissues mounted on slides from several preclinical models. PAH models (Monocrotaline or SuHxNx) LUNGS and HEART (right and left ventricle) PLASMA samples HEART FAILURE models (Isoproterenol or Myocardial infarction) HEART (right and left ventricles) PARKINSON models (6-OHDA and Lactacystine): BRAIN ASTHMA...
SYNCROSOME your dedicated partner for In Vivo Efficacy Studies has been accepted for a poster presentation at NeuroFrance 2019 (Marseille, France, 22-24 May) which is an International Meeting from Société des Neurosciences. Thanks to its CNS expertise our CNS Study Monitor, Dr. Delphine Revy, will present several...
As you know Syncrosome is a preclinical CRO managing efficacy in vivo/ in vitro studies with more than 15 disease models validated in house and highly reproducible. Syncrosome is involved in Central Nervous System activities for 16 years with a specific department dedicated to several CNS...
Multiple studies have been performed to evaluate the effects of mesenchymal stem cells (MSCs) in preclinical Parkinson models. We performed a meta-analysis to estimate the treatment effect of unmodified MSCs on behavioral outcomes in preclinical studies of Parkinson's disease (PD). We performed a systematic literature search...
Alzheimer's disease (AD) is a progressive neuro-psychiatric disorder which is characterized by the formation of senile plaques (SPs), extracellular deposits of amyloid beta-peptides (Aβ) following intracellular neurofibrillary tangles (NFTs) of the microtubule-associated protein tau. Both cause neuronal degeneration, extensive loss of neurons and synaptic loss...
To characterize the expression in skin nerves of native (n-syn) and misfolded phosphorylated (p-syn) α-synucleins in pure autonomic failure (PAF) and idiopathic Parkinson disease (IPD). The specific aims were to (1) define the importance of n-syn and p-syn as disease biomarkers and (2) ascertain differences...
Researchers from the college of Pharmaceutical Sciences in China have recently studied a compound that enhances neuronal recovery in a rat model of Parkinson’s disease (Parkinson 6 OHDA). Parkinson’s disease is a chronic disorder of the central nervous system, caused primarily by the progressive loss...
Syncrosome, participated last week to the Neuroscience R&D Technologies Conference in London, to present key Parkinson's data. It was 2 very interesting days spent to discuss about the new advances in Imaging of Neurodegeneration, Alzheimer and Parkinson’s Disease and Drug Discovery, New trends in Preclinical animal...